Boston ScientificOne Boston Scientific Place
Natick
MA 01760-1537
USA
[t] 001 888-272-1001
|
|
Boston Scientific is the world’s largest medical device company dedicated to developing less-invasive medical devices and procedures.The company delivers more than 15,000 products in over 45 countries and operates 26 manufacturing, distribution and technology centres. Every year Boston Scientific enrolls tens of thousands of patients in pre- and post-approval clinical studies and the company regularly submits news reports on the outcomes of these studies.
|
| |
|
Boston Scientific’s Neuroform EZ Stent System, a fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms is being launched in the USA and Europe. |
28 July 2010 |
| |
|
Boston Scientific enrolls the first patient in its MultiSENSE clinical trial which is designed to evaluate multiple physiologic sensors in the company's COGNIS cardiac resynchronization therapy defibrillators (CRT-Ds). |
12 July 2010 |
| |
|
Boston Scientific receives US Food and Drug Administration approval and launch two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs. |
29 June 2010 |
| |
|
Boston Scientific adds 22 new balloon sizes to the PolarCath Peripheral Dilatation System, including balloon lengths of 120 and 150 mm. |
23 June 2010 |
| |
|
Boston Scientific is launching and announcing the first implants of its Taxus Element Paclitaxel-Eluting Coronary Stent System in the European Union and other CE Mark countries. |
11 June 2010 |
| |
|
Boston Scientific is collaborating with Philips Healthcare and Siemens Medical Solutions to enable the use of its iLab Ultrasound Imaging System with the Philips Allura( Xper and the Siemens AXIOM Artis and Artis zee interventional X-ray systems. |
26 May 2010 |
| |
|
The US Food and Drug Administration gives approval for Boston Scientific’s Latitude 6.0, a software upgrade to the company's Latitude Patient Management system. |
17 May 2010 |
| |
|
Boston Scientific receives CE Mark approval for its Taxus Element Paclitaxel-Eluting Coronary Stent System, the company's third-generation drug-eluting stent (DES) technology. |
17 May 2010 |
| |
|
Boston Scientific is starting the patient enrollment in the EVIDENCE Clinical Trial, which compares the therapeutic effectiveness and cost effectiveness of spinal cord stimulation (SCS) therapy to spine reoperation in patients with failed back surgery syndrome (FBSS). |
06 May 2010 |
| |
|
Boston Scientific is launching the Pelvic Floor Institute - a training forum and online resource designed to enhance physician knowledge and awareness of pelvic floor reconstruction procedures and techniques. |
04 May 2010 |
| |
|
Boston Scientific launches its new Kinetix Guidewire for use in percutaneous coronary intervention (PCI) procedures. |
26 April 2010 |
| |
|
Boston Scientific receives US FDA clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs). |
21 April 2010 |
| |
|
Boston Scientific announces European commercial availability of the company's new cardiac rhythm management connector system, which consists of the Endotak Reliance 4-SITE defibrillation lead and compatible Cognis cardiac resynchronization therapy defibrillators (CRT-Ds) and Teligen implantable cardioverter defibrillators (ICDs). |
26 March 2010 |
| |
|
The Circulatory System Devices Panel of the US Food and Drug Administration unanimously recommends approval of an expanded indication for Boston Scientific’s cardiac resynchronization therapy defibrillators (CRT-Ds), including the Cognis CRT-D. |
22 March 2010 |
| |
|
Boston Scientific reaches the milestone of 1000 European patients using its Latitude Patient Management System which remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status. |
19 March 2010 |
| |
|
Boston Scientific enrolls the first patient in a clinical trial to evaluate its WallFlex Biliary RX Fully Covered Stent for the treatment of benign bile duct strictures. |
15 January 2010 |
| |
|
Boston Scientific receives approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its Promus Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. |
08 January 2010 |
| |
|
Boston Scientific completes enrollment in its MAPS clinical trial, which is studying the coiling of intracranial aneurysms. |
05 January 2010 |
| |
|
Boston Scientific enrolls the first patient in its Taxus Liberte post-approval study which is designed to evaluate real-world clinical outcomes data for the Taxus Liberte Paclitaxel-Eluting Coronary Stent System in combination with a dual antiplatelet therapy drug regimen that includes aspirin and Effient, a new antiplatelet medication. |
04 January 2010 |
| |
|
Boston Scientific receives 510(k) clearance from the US Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent for the treatment of malignant oesophageal strictures (obstructions) caused by tumours in patients with resectable or non-resectable oesophageal cancer. |
20 November 2009 |
| |
|
A public webcast will be held on the 20th October to announce 3rd quarter financial results for Boston Scientific |
12 October 2009 |
| |
|
Fourth stage of MADIT clinical trial series to determine the best strategy for minimising unnecessary therapy for cardiac implant patients |
06 October 2009 |
| |
|
Boston Scientific pays 716 million dollars in lawsuit settlement for patent infringements against Johnson and Johnson |
01 October 2009 |
| |
|
Results from stent trial indicate benefits of use of paclitaxel-eluting stents for treating patients with diabetes |
25 September 2009 |
| |
|
Trials on the Taxus Liberte stent from Boston Scientific demonstrate advantages over the Taxus Express for either small vessels or long lesions |
23 September 2009 |
| |
|
Improved diagnostics and time savings included in the latest release of iLab software for intravascular ultrasound imaging technology |
23 September 2009 |
| |
|
The Platinum clinical program from Boston Scientific has FDA support for trials on the Promus Element Everolimus-Eluting Coronary Stent System |
21 September 2009 |
| |
|
The Bladder Health Network has joined in an alliance with the Urology and Gynaecology business unit of Boston Scientific for marketing testing systems for female urinary incontinence |
15 September 2009 |
| |
|
Boston Scientific has welcomed a leading electrophysiologist onto its Cardiac Rhythm Management Group who will contribute to medical technology development in the company |
02 September 2009 |
| |
|
Boston Scientific receives approval from the US Food and Drug Administration (FDA) to market its Taxus Liberte Long Paclitaxel-Eluting Coronary Stent System, a next-generation drug-eluting stent (DES) designed for long lesions. |
17 July 2009 |
| |
|
Boston Scientific receives the CE Mark for the company’s Latitude Patient Management system which remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status. |
14 July 2009 |
| |
|
Boston Scientific and the University of Rochester Medical Center announces that the landmark MADIT-CRT trial has met its primary endpoint. |
23 June 2009 |
| |
|
Boston Scientific receives 510(k) clearance from the US Food and Drug Administration (FDA) to market its SpyScope Access and Delivery Catheter for diagnostic and therapeutic applications during endoscopic procedures in the pancreatico-biliary system. |
01 June 2009 |
| |
|
Boston Scientific is welcoming publication of results from the ISAT clinical trial showing patients with a ruptured intracranial aneurysm treated with endovascular coil embolization are 23 percent less likely to die within five years compared to patients who undergo surgical clipping. |
27 May 2009 |
| |
|
Boston Scientific receives approval from the US Food and Drug Administration (FDA) to market its Taxus Liberte Atom Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. |
27 May 2009 |
| |
|
Boston Scientific starts patient enrollment in the ORION clinical trial, which is designed to evaluate the company's EPIC Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease that impacts a patient's lower extremities. |
22 May 2009 |
| |
|
Boston Scientific releases results from an analysis of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial.
|
22 May 2009 |
| |
|
Boston Scientific launches the platinum chromium Taxus Element Paclitaxel-Eluting Coronary Stent System in select markets worldwide. |
20 May 2009 |
| |
|
Boston Scientific announces positive outcomes from a substudy of patients with left main coronary disease who were treated with the Taxus Express2 Paclitaxel-Eluting Coronary Stent System. |
20 May 2009 |
| |
|
Boston Scientific announces that an analysis of long-term data from the MADIT II clinical study shows that the life-saving benefits of implantable cardioverter defibrillator (ICD) therapy remain sustainable at eight years. |
14 May 2009 |
| |
|
The first human implants of the Boston Scientific's Endotak Reliance 4-Site defibrillation lead system have been completed. |
13 May 2009 |
| |
|
Boston Scientific announces results from an analysis of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial. |
30 March 2009 |
| |
|
Three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials have been at the 58th Annual Scientific Session of the American College of Cardiology. |
30 March 2009 |
| |
|
Boston Scientific launches the company's iCross Coronary Imaging Catheter, a product designed to improve the deliverability of the intravascular ultrasound (IVUS) technology, the iLab Ultrasound Imaging System. |
20 March 2009 |
| |
|
Boston Scientific has launched its Taxus Liberte Paclitaxel-Eluting Coronary Stent System in Japan |
03 March 2009 |
| |
|
Boston Scientific has welcomed the publication of results from the company’s SYNTAX trial in this week's issue of the New England Journal of Medicine. |
19 February 2009 |
| |
|
Boston Scientific has submitted to the US Food and Drug Administration (FDA) the final modules of the company's Pre-Market Approval (PMA) applications for both its Taxus Liberte Atom Paclitaxel-Eluting Coronary Stent System and its Taxus Liberte Long Paclitaxel-Eluting Coronary Stent System. |
05 February 2009 |
| |
|
Boston Scientific has begun patient enrollment in the PLATINUM clinical trial, which is designed to evaluate the company's Promus Element Everolimus-Eluting Coronary Stent. |
03 February 2009 |
| |
|
Boston Scientific has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its Taxus Liberte Paclitaxel-Eluting Coronary Stent System. |
28 January 2009 |
| |
|
The US Department of Veterans Affairs (VA) has awarded a contract to Boston Scientific for a full range of the company's pacemakers and defibrillators. |
20 January 2009 |
| |
|
Boston Scientific has acquired Labcoat, a privately held, development-stage drug-eluting stent technology company based in Galway, Ireland. |
06 January 2009 |
| |
|
Boston Scientific has enrolled the first patient in the CABANA post-market approval study of the company's Carotid Wallstent Monorail Endoprosthesis used in conjunction with its FilterWire EZ Embolic Protection System. |
19 December 2008 |
| |
|
The US Food and Drug Administration (FDA) has approved Boston Scientific’s Express SD Renal Monorail Premounted Stent System for use as an adjunct to PTRA (percutaneous transluminal renal angioplasty) in certain lesions of the renal arteries. |
15 December 2008 |
| |
|
Boston Scientific has received approval from the US Food and Drug Administration to market its Apex PTCA Dilatation Catheter. |
10 November 2008 |
| |
|
Boston Scientific has welcomed an announcement by the UK's National Institute for Health and Clinical Excellence (NICE) recommending the use of spinal cord stimulation (SCS) for patients with chronic neuropathic pain. |
27 October 2008 |
| |
|
The US Food and Drug Administration (FDA) has approved Boston Scientific’s Carotid Wallstent Monorail Endoprosthesis for the treatment of patients with carotid artery disease who are at high risk for surgery. |
24 October 2008 |
| |
|
Boston Scientific’s WallFlex Biliary RX Stent (Ref 1) for the palliative treatment of malignant common bile duct strictures has been introduced in Europe. |
17 October 2008 |
| |
|
Boston Scientific has announced results from an analysis of the HORIZONS AMI trial, which is sponsored by the Cardiovascular Research Foundation (CRF) with research grant support from Boston Scientific and The Medicines Company, and is designed to determine the safety and efficacy of the Taxus Express2 Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients experiencing an acute myocardial infarction (AMI), commonly referred to as a heart attack. |
16 October 2008 |
| |
|
Boston Scientific has announced positive one-year results from the Intercontinental and European launch phases of its global Taxus OLYMPIA registry, the world's largest prospective, post-approval registry for a single drug-eluting stent (DES). |
15 October 2008 |
| |
|
Comprehensive data has been announced by Boston Scientific from the Taxus ATLAS clinical programme, a series of global, prospective, multi-centre, single-arm, historically controlled trials, which evaluated the Taxus Liberte Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. |
13 October 2008 |
| |
|
Boston Scientific has announced results from an analysis of almost 7,500 patients from its Taxus ARRIVE 1 and 2 registries, which are designed to confirm the performance of the Taxus Express2 Paclitaxel-Eluting Coronary Stent System in real-world practice. |
13 October 2008 |
| |
|
Boston Scientific and GE Healthcare have collaborated to enable improved intravascular ultrasound (IVUS) workflow between the GE Healthcare Innova Cardiovascular X-ray System and the Boston Scientific iLab Ultrasound Imaging System. |
13 October 2008 |
| |
|
Boston Scientific has received approval from the US FDA to market its second-generation Taxus Liberte Paclitaxel-Eluting Coronary Stent System. |
10 October 2008 |
| |
|
Boston Scientific has completed enrollment in the Perseus trial, which is designed to evaluate the company's third-generation Taxus Element paclitaxel-eluting coronary stent. |
08 October 2008 |
| |
|
Boston Scientific has opened the International Institute for Therapy Advancement in Paris to provide world-class training and education to help healthcare professionals advance the standard of patient care. |
29 September 2008 |
| |
|
Boston Scientific has received approval from the US FDA to market its Taxus Express2 Atom Paclitaxel-Eluting Coronary Stent System. |
25 September 2008 |
| |
|
Boston Scientific has released one-year results from the European and Intercontinental launch phases of its global Taxus OLYMPIA registry, the world's largest post-approval, prospective registry for a single drug-eluting stent (DES). |
02 September 2008 |
| |
|
Boston Scientific has released one-year data from its landmark SYNTAX trial comparing percutaneous coronary intervention (PCI) using the Taxus Express2 Paclitaxel-Eluting Coronary Stent System to contemporary coronary artery bypass graft (CABG) surgery. |
01 September 2008 |
| |
|
The US Food and Drug Administration (FDA) has approved the Promus Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. |
03 July 2008 |
| |
|
The US Green Building Council has given Boston Scientific Leadership in Energy and Environmental Design (LEED) certification for the renovation of the company Endosurgery Headquarters located in Marlborough, Massachusetts. |
29 May 2008 |
| |
|
Boston Scientific has completed its acquisition of CryoCor. |
28 May 2008 |
| |
|
Boston Scientific has released results from an international, multi-centre patient registry documenting favourable safety and clinical utility data for its SpyGlass Direct Visualization System, which offers extensive visual access to the biliary tract. |
21 May 2008 |
| |
|
Boston Scientific has received US FDA approval of its Acuity Spiral left ventricular lead for use with cardiac resynchronization therapy defibrillators (CRT-D) and cardiac resynchronization therapy pacemakers (CRT-P), both of which treat heart failure. |
19 May 2008 |
| |
|
Boston Scientific has expanded the size range of the company’s FilterWire EZ Embolic Protection System with a new 2.25 to 3.5mm device. |
19 May 2008 |
| |
|
Boston Scientific has introduced a new clinical science initiative, Altitude, which will analyse data from the Latitude Patient Management system. |
16 May 2008 |
| |
|
Boston Scientific has received US FDA approval of its Cognis cardiac resynchronization therapy defibrillator (CRT-D) and Teligen implantable cardioverter defibrillator (ICD). |
14 May 2008 |
| |
|
Boston Scientific has released results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the Taxus Express Paclitaxel-Eluting Coronary Stent System in real-world practice. |
13 May 2008 |
| |
|
Boston Scientific has received US FDA approval of the company’s Altrua family of pacemakers. |
08 May 2008 |
| |
|
Boston Scientific has received CE Mark approval and has launched its Altrua family of pacemakers in Europe. |
07 May 2008 |
| |
|
Boston Scientific has been completed enrollment for the Multicentre Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). |
24 April 2008 |
| |
|
The GHXcellence Awards for achievements in improving supply chain performance has named Boston Scientific as the US Healthcare Supplier of the Year. |
24 April 2008 |
| |
|
Boston Scientific has received approval for the sale of its Taxus Liberte paclitaxel-eluting coronary stent system in Canada. |
17 April 2008 |
| |
|
CryoCor and Boston Scientific have signed a definitive merger agreement, under which Boston Scientific will pay a cash purchase price of $1.35 per share of CryoCor, or approximately $17.6 million. |
16 April 2008 |
| |
|
The Japanese Ministry of Health, Labor and Welfare (MHLW) has given approval of Boston Scientific’s Acuity Steerable left ventricular lead for use with cardiac resynchronization therapy (CRT) devices, which treat heart failure. |
15 April 2008 |
| |
|
Boston Scientific and Surgi-Vision have reached a licensing and development arrangement for magnetic resonance imaging (MRI)-safe technology. |
15 April 2008 |
| |
|
Boston Scientific has sold Boston Scientific Santa Rosa , formerly known as TriVascular, to TV2 Holding, a privately held company based in Santa Rosa, California. Boston Scientific Santa Rosa holds equipment and intellectual property related to the TriVascular endovascular aortic repair (EVAR) programme. |
31 March 2008 |
| |
|
Boston Scientific has released results from an analysis of two-year data from more than 7,000 patients in the Taxus Arrive Registry programme. |
31 March 2008 |
| |
|
Boston Scientific has released results from an analysis of 4,772 patients from its Taxus Arrive 1 and 2 registries that were designed to assess the performance of the Taxus Express2 Paclitaxel-Eluting Coronary Stent System in real-world practice. |
31 March 2008 |
| |
|
Boston Scientific has received CE Mark approval of the company’s Acuity
Spiral left ventricular lead for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, both of which treat heart failure.
|
03 March 2008 |
| |
|
Boston Scientific has sold the company’s Fluid Management and Venous Access businesses to Avista Capital Partners for $425 million in cash. |
15 February 2008 |
| |
|
Boston Scientific has been enrolled the first patient in its PROENCY (Promus, ENdeavor and CYpher) European registry to observe different 'Olimus'-eluting coronary stents |
11 February 2008 |
| |
|
Boston Scientific has launched an educational initiative in the USA called ‘Close the Gap’ that aims to address disparities in cardiovascular care for the underserved patient populations of women, black Americans and Latino Americans. |
05 February 2008 |
| |
|
Boston Scientific has received CE Mark approval for the company’s Cognis cardiac resynchronisation therapy defibrillator (CRT-D) and Teligen implantable cardioverter defibrillator (ICD). |
22 January 2008 |
| |
|
Boston Scientific has completed the sale of the controlling interests in its auditory business and drug pump development programme to former principals and shareholders of Advanced Bionics. |
07 January 2008 |
| |
|
Boston Scientific has completed the sale of its Cardiac Surgery and Vascular Surgery businesses to the Swedish Getinge Group for $750 million. |
07 January 2008 |
| |
|
Boston Scientific's cardiac resynchronization therapy defibrillator (CRT-D) has received the CE Mark approval.
|
28 December 2007 |
| |
|
Boston Scientific’s Taxus Liberte paclitaxel-eluting coronary stent system has received European CE Mark approval for use in patients with diabetes (Ref 1). |
24 December 2007 |
| |
|
Boston Scientific and Avista Capital Partners, a leading private equity firm, have signed a definitive agreement under which Avista will acquire from Boston Scientific its Fluid Management and Venous Access businesses for $425 million in cash. |
14 December 2007 |
| |
|
Boston Scientific has welcomed a US Food and Drug Administration (FDA) advisory panel's recommendation to approve with conditions the Promus/ Xience V everolimus-eluting coronary stent system. |
30 November 2007 |
| |
|
Boston Scientific has announced that an amended agreement has been reached to settle claims associated with a series of product communications issued by Guidant in 2005 and 2006. |
19 November 2007 |
| |
|
Boston Scientific and GE Healthcare have announced the industry's first patient data integration between a cardiac rhythm management remote monitoring system and a physician's electronic medical record (EMR). |
06 November 2007 |
| |
|
A definitive agreement has been signed by Boston Scientific for the sale of its Cardiac Surgery and Vascular Surgery businesses to the Getinge Group. |
05 November 2007 |
| |
|
Positive three-year results from the Cabernet and Beach carotid artery stenting clinical trials has been announced by Boston Scientific. |
24 October 2007 |
| |
|
Boston Scientific has announced five year and final follow-up data from its Taxus IV clinical trial. |
22 October 2007 |
| |
|
Boston Scientific has revealed nine month data from the pivotal Taxus Atlas Small Vessel and Long Lesion studies, which evaluate the Taxus Liberte Paclitaxel-Eluting Stent System in complex lesions. |
22 October 2007 |
| |
|
Boston Scientific has welcomed results from the SPIRIT III Clinical Trial, which continue to support the proven safety and efficacy of the Taxus Express2 Paclitaxel-Eluting Coronary Stent System and add to the growing body of strong clinical evidence for the Xience V (Promus) Everolimus Eluting Coronary Stent System. |
22 October 2007 |
| |
|
Boston Scientific has received CE Mark approval for its Confient implantable cardioverter defibrillator (ICD) which is first Boston Scientific-branded cardiac rhythm management device to treat sudden cardiac death (SCD).
|
09 October 2007 |
| |
|
Boston Scientific has received CE Mark approval for its Confient implantable cardioverter defibrillator (ICD). |
09 October 2007 |
| |
|
Boston Scientific has signed a definitive agreement to purchase Remon Medical Technologies |
26 June 2007 |
| |
|
Boston Scientific has purchased technology for treating symptomatic benign prostatic hyperplasia (BPH, often referred to as enlarged prostate) from Celsion. |
22 June 2007 |
| |
|
Boston Scientific has welcomed an article in the Journal of American College of Cardiology (JACC) that reviews the Taxus Atlas and evaluates the company's second-generation Taxus Liberte paclitaxel-eluting stent system. |
04 June 2007 |
| |
|
Boston Scientific has enrolled the first patient in the Sonoma post-market approval study of the company's NexStent Carotid Stent System that is used in conjunction with the FilterWire EZ Embolic Protection System.
|
01 June 2007 |
| |
|
TheTaxus Liberte Long paclitaxel-eluting coronary stent system from Boston Scientific has received the CE Mark.
allowing doctors to treat longer coronary artery lesions with a single stent. |
24 May 2007 |
| |
|
Boston Scientific has announced the four year follow-up data from the Taxus VI clinical trial. |
23 May 2007 |
| |
|
A new study assesses more than 7,000 patients as part of paclitaxel-eluting coronary stent trial. |
23 May 2007 |
| |
|
Additional data from the Spirit First, II and III clinical trials reaffirms prior safety and and efficacy data for the Taxus Express2 Paclitaxel-Eluting Coronary Stent System and Xience V (Promus) Everolimus Eluting Coronary Stent System. |
23 May 2007 |
| |
|
A large independent registry has confirmed the benefit of closed-cell stents in patients with carotid artery stenosis. |
22 May 2007 |
| |
|
Boston Scientific has finalised enrollment in the European and Intercontinental phases (II and III) of its Taxus Olympia registry to bring the number of current patients to more than 23,000. |
14 May 2007 |
| |
|
Data reflecting clinical event notification statistics from the first 10,000 patients monitored on the Latitude Patient Management System has been released by Boston Scientific. |
09 May 2007 |
| |
|
Boston Scientific has launched the Taxus Express2 paclitaxel-eluting coronary stent system in Japan. |
08 May 2007 |
| |
|
Boston Scientific has revealed two year results from the Renaissance study that was designed to evaluate the safety and effectiveness of the company's Express SD Renal Stent in hypertensive patients with atherosclerotic renal artery stenosis (RAS). |
04 May 2007 |
| |
| |
